Novartis Launches Japan Compliance Advisory Board In Wake Of Diovan Turmoil
This article was originally published in PharmAsia News
Executive Summary
Novartis Pharma in Japan established a compliance advisory board as part of a move to salvage its tarnished image with ongoing Diovan scandals.